Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
403 studies found for:    PD-1
Show Display Options
Rank Status Study
21 Completed PD-1/PD-L1 Pathway Study on Septic Patients
Condition: Sepsis
Intervention:
22 Recruiting Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Radiation: Radiotherapy;   Biological: Rituximab;   Biological: Autologous dendritic cells;   Biological: GM-CSF;   Biological: Pembrolizumab
23 Suspended Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: CT-011 (Anti-PD1 Antibody);   Other: Sipuleucel-T (Provenge);   Drug: Cyclophosphamide
24 Recruiting Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Conditions: Melanoma (Skin);   Skin Cancer
Interventions: Drug: Nivolumab;   Procedure: Surgery to Remove Tumor for Growth of TIL;   Drug: CD137;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: TIL Infusion;   Drug: Interleukin-2
25 Active, not recruiting 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MK-3475;   Drug: Pomalidomide;   Drug: Dexamethasone
26 Not yet recruiting Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Nivolumab;   Radiation: Radiation
27 Recruiting A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)
Condition: Advanced Melanoma
Intervention: Drug: Pembrolizumab
28 Recruiting Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
Conditions: Breast Neoplasms;   Bone Neoplasms
Interventions: Radiation: Stereotactic Ablative Body Radiosurgery (SABR);   Drug: MK-3475
29 Not yet recruiting Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
Conditions: Carcinoma, Non-small-cell Lung;   Mesothelioma;   Pancreatic Neoplasms
Interventions: Drug: Defactinib;   Drug: Pembrolizumab
30 Recruiting Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Condition: Neoplasms by Site
Interventions: Biological: BMS-986016;   Biological: BMS-936558
31 Active, not recruiting Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: NY-ESO-1 157-165 (165V);   Drug: Nivolumab;   Biological: gp100:280-288 (288V);   Drug: Montanide ISA 51 vegetable grade (VG);   Drug: Ipilimumab;   Procedure: Apheresis Procedure
32 Not yet recruiting RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
Condition: Urothelial Cancer
Interventions: Drug: PEMBROLIZUMAB;   Radiation: hypofractionated radiation
33 Active, not recruiting A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
Condition: Advanced Solid Tumors
Interventions: Drug: PF-05082566;   Drug: MK-3475
34 Recruiting Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Condition: Melanoma
Intervention: Drug: Pembrolizumab and Ipilimumab combination
35 Recruiting Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Nivolumab
36 Not yet recruiting Anti PD-1 Neo-adjuvant Treatment for NSCLC
Conditions: Non Small Cell Lung Carcinoma;   Stage I;   Stage II
Interventions: Drug: Pembrolizumab 200 mg IV single dose;   Drug: Pembrolizumab 200 mg IV twice interval 21 days;   Drug: Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d;   Drug: Pembrolizumab 100 mg I.V single dose;   Procedure: Surgical resection of tumor
37 Active, not recruiting AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer;   Colorectal Neoplasms;   Colorectal Carcinoma
Interventions: Drug: AMP-224;   Radiation: Stereotactic Body Radiation Therapy(SBRT);   Drug: Cyclophosphamide
38 Recruiting A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Interventions: Drug: TSR-022;   Drug: anti PD-1 antibody
39 Recruiting E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers
Conditions: Cervical Cancer;   Vaginal Cancer;   Anal Cancer;   Penile Cancer;   Oropharyngeal Cancer
Interventions: Biological: E7 TCR cells;   Drug: pembrolizumab;   Drug: aldesleukin;   Drug: fludarabine;   Drug: cyclophosphamide
40 Recruiting Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Condition: Melanoma
Interventions: Drug: ipilimumab;   Drug: nivolumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.